The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping

Table 1

Demographic and clinical characteristics: T = temporal, F = frontal, P = parietal, O = occipital, F-P = frontoparietal, 3D-CRT = three-dimensional conformal radiotherapy, and IMRT = intensity-modulated radiotherapy.

Characteristic
Age at initial diagnosis (years)
Median	52.5
Range	29–66
Sex ()
Men	17 (65%)
GBM location (%)
T/F/P/O/F-P	36/28/21/7/8
Radiotherapy
Median dose (Gy)	60
Technique 3D-CRT/IMRT (%)	50/50
Cycles of adjuvant TMZ
Median	6
Range	4–10
Time to graphic progression (months)
Mean	5.8
SD	5.6
Diagnosis validation
Biopsy/subsequent imaging (%)	67/33
Final diagnosis
Tumor recurrence	18 (75%)
Pseudoprogression	6 (25%)